These data, in conjunction with decreased expression of immune-suppressive markers, PD-L1 and CD84, indicate in vivo OPN5 treatment functionally reverses the immune-suppressive activity and mechanisms of CLL-associated MDSCs. The gene discussed is CD274; the disease is B-cell chronic lymphocytic leukemia.